Development of conjugated secondary antibodies for wildlife disease surveillance

Show simple item record

dc.contributor.author Ochai, Sunday Ochonu
dc.contributor.author Crafford, Jan Ernst
dc.contributor.author Kamath, Pauline L.
dc.contributor.author Turner, Wendy C.
dc.contributor.author Van Heerden, Henriette
dc.date.accessioned 2024-06-18T04:22:08Z
dc.date.available 2024-06-18T04:22:08Z
dc.date.issued 2023-07-11
dc.description DATA AVAILABILITY STATEMENT : The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author. en_US
dc.description.abstract Disease monitoring in free-ranging wildlife is a challenge and often relies on passive surveillance. Alternatively, proactive surveillance that relies on the detection of specific antibodies could give more reliable and timely insight into disease presence and prevalence in a population, especially if the evidence of disease occurs below detection thresholds for passive surveillance. Primary binding assays, like the indirect ELISA for antibody detection in wildlife, are hampered by a lack of species-specific conjugates. In this study, we developed anti-kudu (Tragelaphus strepsiceros) and anti-impala (Aepyceros melampus) immunoglobulin-specific conjugates in chickens and compared them to the binding of commercially available protein-G and protein-AG conjugates, using an ELISA-based avidity index. The conjugates were evaluated for cross-reaction with sera from other wild herbivores to assess future use in ELISAs. The developed conjugates had a high avidity of >70% against kudu and impala sera. The commercial conjugates (protein-G and protein-AG) had significantly low relative avidity (<20%) against these species. Eighteen other wildlife species demonstrated cross-reactivity with a mean relative avidity of >50% with the impala and kudu conjugates and <40% with the commercial conjugates. These results demonstrate that species-specific conjugates are important tools for the development and validation of immunoassays in wildlife and for the surveillance of zoonotic agents along the livestock-wildlife-human interface. en_US
dc.description.department Veterinary Tropical Diseases en_US
dc.description.librarian am2024 en_US
dc.description.sdg SDG-03:Good heatlh and well-being en_US
dc.description.sponsorship NSF Grant. en_US
dc.description.uri http://www.frontiersin.org/Immunology en_US
dc.identifier.citation Ochai, S.O., Crafford, J.E., Kamath, P.L., Turner, W.C. & Van Heerden, H. (2023) Development of conjugated secondary antibodies for wildlife disease surveillance. Frontiers in Immunology 14:1221071. DOI: 10.3389/fimmu.2023.1221071 en_US
dc.identifier.issn 1664-3224 (online)
dc.identifier.other 10.3389/fimmu.2023.1221071
dc.identifier.uri http://hdl.handle.net/2263/96501
dc.language.iso en en_US
dc.publisher Frontiers Media en_US
dc.rights © 2023 Ochai, Crafford, Kamath, Turner and van Heerden. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). en_US
dc.subject Wildlife species en_US
dc.subject Adaptive immunity en_US
dc.subject Avidity en_US
dc.subject Conjugates en_US
dc.subject Diagnostics en_US
dc.subject Enzyme-linked immunosorbent assay (ELISA) en_US
dc.subject Passive disease surveillance en_US
dc.subject SDG-03: Good health and well-being en_US
dc.title Development of conjugated secondary antibodies for wildlife disease surveillance en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record